Even specific DPP4 inhibitors have potential side effects (gastro-intestinal, cardiovascular, infective, inflammatory, and allergic events) due to their prolonging the action of a number of neuropeptides and chemokines as well as to their non-enzymatic functions.
Research models examine how this preservative supports sterility across repeated use scenarios under controlled conditions
Bioavailability after subcutaneous injection is approximately 4-5%, which is typical for peptide therapeutics
PubMed Central, Zhang, Jiao-Jiao, et al
Avoid repeated freezing and thawing, which may accelerate degradation
Your doctor will make the call based on your situation and how you respond to the initial treatment